The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
Document title: The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000411345
ISSN: 1665-2681
Authors: 1
2
1
1
1
3
1
Institutions: 1Shandong University, Jinan Infectious Disease Hospital, Jinan, Shandong. China
2Shandong University, School of Medicine, Jinan, Shandong. China
3Shandong University, Qianfoshan Hospital, Jinan, Shandong. China
Year:
Season: Mar-Abr
Volumen: 14
Number: 2
Pages: 150-160
Country: México
Language: Inglés
Document type: Artículo
Approach: Analítico, descriptivo
English abstract The effectiveness of nucleoside analogue (NA) treatment in patients with chronic hepatitis B (CHB) -associated liver failure is still controversial. Severe lactic acidosis has been reported during entecavir (ETV) treatment in patients with impaired liver function. Aim. To investigate the rescuing efficacy and safety of ETV in patients with CHB-associated liver failure. Material and methods. A literature search was carried out to collect articles dated up to December, 2013 on ETV therapy for patients with CHB-associated liver failure. Risk ratio (RR) and mean difference (MD) were used to measure the effects. Survival rate was used as the primary efficacy measure. The safety of ETV was assessed. Results. Six randomized controlled trials were selected. The overall analysis revealed ETV significantly improved survival at 4 weeks (RR = 1.35; 95% CI [1.16, 1.57]; p < 0.0001), 8 weeks (RR = 1.33; 95% CI [1.07, 1.64]; p = 0.009), 12 weeks (RR = 1.68; 95% CI [1.24, 2.28]; p = 0.0008). Pooled data also showed beneficial effects of antiviral therapy compared with control for HBV DNA negative change (RR = 5.35; 95% CI [2.06, 13.88]; p = 0.0006), TBIL and PTA improvement (TBIL: MD = -69.36; 95% CI [-134.37, -4.36]; p = 0.04. PTA: MD = 16.26; 95% CI [8.59, 23.94]; p < 0.0001). No adverse effect was identified in the examined studies. Conclusion. Our results showed that antiviral therapy with ETV improved the short-term survival of patients with CHB-associated liver failure. In addition, ETV was well tolerated during the treatment period. Further studies are still needed to strengthen these results
Disciplines: Medicina
Keyword: Farmacología,
Gastroenterología,
Hepatitis B,
Hepatitis crónica,
Falla hepática,
Entecavir
Keyword: Medicine,
Gastroenterology,
Pharmacology,
Hepatitis B,
Chronic hepatitis,
Liver failure,
Entecavir
Full text: Texto completo (Ver PDF)